Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04705168 · ClinicalTrials.gov registry record
Study of the Nevisense Device to Assess Atypical Skin Lesions
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 40
- Enrollment target
NCT04705168: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04705168 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04705168 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether the Nevisense device can provide useful information about atypical moles to complement the usual assessments done during routine screening for melanoma. Assessing particpants' moles with the Nevisense device may help improve screening methods for the early detection of melanoma in people with atypical mole syndrome.
Interventions
- DIAGNOSTIC_TEST Nevisense electrical impedance spectroscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-01-08 |
| Est. Completion | 2025-11-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04705168
The ClinicalTrials.gov registry entry for NCT04705168 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nevisense electrical impedance spectroscopy is the first listed.
NCT04705168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04705168 about?
NCT04705168 is a clinical study titled "Study of the Nevisense Device to Assess Atypical Skin Lesions". The purpose of this study is to find out whether the Nevisense device can provide useful information about atypical moles to complement the usual assessments done during routine screening for melanoma. Assessing particpants' moles with the Nevisense device may help improve screening methods for the ...
What is the current status of trial NCT04705168?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2021-01-08. Estimated completion is 2025-11-18.
What interventions are being tested in trial NCT04705168?
The interventions under investigation include: Nevisense electrical impedance spectroscopy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04705168?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.